Key result
Next-generation Pt(IV) prodrugs and nanoscale delivery systems may overcome resistance and reduce toxicity in ovarian cancer.
Why the study?
Platinum-based chemotherapy remains foundational in ovarian cancer but is limited by toxicity and resistance, while high costs and stratification issues restrict first-line use of newer therapies.
Advances in platinum chemistry and nanotechnology offer a promising strategy to overcome resistance and toxicity in ovarian cancer therapy, maintaining its role as a foundational treatment.
Answers are grounded in this paper and cite their sources.
Warrants prospective trials of Pt(IV) prodrugs and nanodelivery in ovarian cancer; leaves open clinical impact on resistance and toxicity.
Platinum (Pt)-based chemotherapy has served for decades as the foundation of ovarian cancer therapy. Yet, its gains are always undermined by severe toxic side effects and drug resistance. Although a new generation of therapy - including anti-angiogenic drugs, PARP inhibitors, ADCs, and immune checkpoint inhibitors- has emerged, issues of costs and patient stratification have limited their use as first line treatment. Hence, platinum-based drugs won't be easily surpassed by newer modalities in the immediate future, providing a window of opportunities to make them work more efficiently. This review re-evaluates the future of platinum therapies by exploring key strategies to counteract resistance mediated by intracellular mechanisms and the complex tumour microenvironment. One approach includes converting non-specific and reactive FDA-approved Pt(II) agents into the next-generation Pt(IV) prodrugs, which are stable, single/dual/multi-action or stimuli-triggered agents that become activated only inside target cells, releasing their original Pt(II) counterparts and two additional axial ligands. A second approach includes the development of advanced nanoscale delivery systems to enhance the amount of chemotherapeutic reaching the tumour site while minimizing off target effects. These nanotechnology platforms span from liposomes to virus-like particles and can be engineered to bypass biological obstacles while avoiding premature elimination from the body, even though they are associated with immunogenic reactions. By uniting advances in platinum chemistry with the precision offered by modern nanotechnology, a new therapeutic paradigm emerges-one that can enhance efficacy, reduce systemic toxicity, and offer a more accessible alternative to costly biologics, thereby securing a renewed and enduring role for platinum in ovarian cancer treatment.
No takes yet. Share an insight, caveat, or question.
Roa et al. (2026) conducted a review in Ovarian cancer. Platinum therapies (Pt(IV) prodrugs and nanoscale delivery systems) was evaluated. Next-generation Pt(IV) prodrugs and advanced nanoscale delivery systems offer strategies to overcome resistance and reduce toxicity of platinum-based therapies in ovarian cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: